China's Q1 industrial profits return to growth amid tariff woes
BEIJING: China's industrial profits returned to growth in the first quarter, official data showed on Sunday, but are likely to come under further pressure amid a trade war with the United States.
With Washington's aggressive tariffs threatening to hit China's crucial export engine hit and no time frame yet for any bilateral trade talks, economists and investors are waiting for the Chinese government to roll out more support measures to cushion the blow to the world's second-largest economy.
Cumulative profits of China's industrial firms rose 0.8% to 1.5 trillion yuan ($205.86 billion) in the first quarter from a year earlier, the National Bureau of Statistics (NBS) data showed, reversing a 0.3% decline in the first two months.
In March alone, profits rose 2.6% on-year.
China's Q1 automobile exports up 16% y/y, industry official says
The profit gain in the first quarter followed a 3.3% fall in 2024, reversing the trend of continuous declines in cumulative profits of enterprises since the third quarter of last year, Yu Weining, an NBS statistician, said in a separate statement along with the data release.
Thanks to a consumer goods trade-in campaign, profits in the wearable smart device manufacturing sector soared by 78.8% while those for household kitchen appliance makers rose 21.7%, said the statement.
China reported stronger-than-expected economic growth in the first quarter as government stimulus boosted consumption and supported investment, but deflationary pressures persisted, ripping into corporate profits and workers' incomes as firms tried to navigate rising trade disruptions.
'At the current stage, the external environment is becoming more complex and severe, and unstable and uncertain factors are increasing,' said Yu, adding the government will further strengthen policy implementation and promote the continuous improvement of corporate profitability.
Beijing has made increasingly louder calls on exporters to find local buyers as an alternative to the US market, now effectively frozen after Washington hiked tariffs on Chinese goods by 145%, but many export-reliant factories have decried weak domestic demand, price wars, low profits and payment delays in the Chinese market.
The ruling Communist Party's Politburo on Friday pledged to support firms and workers most affected by the impact of US tariffs, also saying new monetary tools and policy financing instruments will be set up to boost innovation, consumption and foreign trade.
Profits at state-owned firms dipped 1.4% in the first quarter. Private-sector companies saw a 0.3% fall, but foreign firms recorded a 2.8% gain, according to a breakdown of the NBS data.
Industrial profit numbers cover firms with annual revenue of at least 20 million yuan from their main operations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
4 hours ago
- Business Recorder
Russian rouble gains as oil prices jump on Middle East tensions
The rouble gained against the dollar on Friday, supported by a sharp jump in prices for oil, Russia's main export, after Israel launched major strikes against Iran. Israel said it had attacked nuclear facilities and missile factories and killed a swathe of military commanders in what could be a prolonged operation to prevent Tehran building an atomic weapon. The attacks sparked Iranian retaliation and raised concerns about possible disruption to oil supplies. Brent crude was up 7.9% at $74.83 a barrel by 1124 GMT. The rouble was 0.6% higher at 79.50 per U.S. dollar, according to LSEG data based on over-the-counter quotes. Trading was light, as Russia was marking a two-day national holiday. The rouble appreciated more sharply earlier in the session, but as oil prices pared some of their early gains, so too did the Russian currency. The rouble has strengthened by over 40% against the dollar this year, a rise analysts have attributed to the easing of geopolitical tensions - mainly with U.S. President Donald Trump's administration - and the central bank's tight monetary policy, which has reduced demand for foreign currency. Against the Chinese yuan, the most traded foreign currency in Russia, the rouble strengthened by 0.3% to 10.92 on the Moscow Stock Exchange. The central bank uses yuan for foreign exchange interventions.
Business Recorder
4 hours ago
- Business Recorder
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally,' AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
Business Recorder
5 hours ago
- Business Recorder
India, China agree to expedite resumption of direct flights as ties improve
India and China have agreed to expedite the resumption of direct air services and step up communication, the two countries' foreign ministries said on Friday, as Beijing and New Delhi continue to mend bilateral ties. The ministries' statements came after a meeting on Thursday of Indian Foreign Secretary Vikram Misri and Chinese Vice Foreign Minister Sun Weidong, who is visiting India. The two countries reached an agreement in October regarding patrolling along their Himalayan border, thawing a standoff that began in 2020 and had strained bilateral ties, impacting areas from trade to technology to air travel. China expresses concern, offers help to resolve Pakistan, India conflict Sun said in the meeting that the two sides should properly handle disputes and differences, and jointly play a constructive role in maintaining international and regional peace and stability, according to the Chinese ministry's statement. The two sides agreed to continue to stabilise and rebuild ties, the Indian ministry's statement said. In January, the neighbours agreed to work on resolving trade and economic differences, a move expected to boost their aviation sectors.
